In patients with follicular lymphoma being treated in the third-line setting or later, liso-cel therapy is associated with durable responses.

Targeted immunotherapy significantly improved responses and prolonged survival in newly-diagnosed Ph+ ALL compared with chemotherapy.

Treatment with rituximab plus epcoritamab has achieved rapid and deep responses in follicular lymphoma patients with a high tumor burden.

KRd significantly prolonged progression-free survival and improved the MRD negativity rate compared to VRd in newly diagnosed multiple myeloma.

The Isa-VRd quadruplet regimen induced sustained MRD negativity and a strong rate complete response or better in patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM).

In patients with advanced-stage classic Hodgkin lymphoma, a PFS benefit was seen at 3 years’ follow-up with N-AVD compared to BV-AVD.

R-CHOP plus ibrutinib, followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC DLBCL.

Standard-risk rel/ref multiple myeloma patients with benefit from earlier treatment with cilta-cel, rather than waiting for later lines of therapy.

Investigators analyzed IBD subtypes and their associated risks of radical prostatectomy complications among a cohort of patients with prostate cancer to fill a knowledge gap.

Investigators sought to examine the connection between a diagnosis of cancer within 12 months following a diagnosis of hiccups ...

Researchers sought to determine whether adding fixed-duration venetoclax to RBAC in the first line would be effective in older patients with high-risk MCL.

FZOCUS-1 assessed the safety and efficacy of fuzuloparib alone and in combination with apatinib for patients with newly diagnosed or advanced ovarian cancer.